Dr. Reddy’s (NYSE: RDY) appoints biologics chief and Deloitte as US auditor

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited reports that its board approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics, Senior Management Personnel and member of the Management Council, effective July 22, 2026. An updated list of the company’s Senior Management Personnel reflects this addition.

The board also approved the appointment of Deloitte Haskins & Sells LLP as the company’s Independent Registered Public Accounting Firm to audit financial statements included in the Annual Report on Form 20-F and review interim financial statements filed on Form 6-K. This aligns with an earlier decision to appoint Deloitte Haskins & Sells LLP as statutory auditors for a term of five consecutive years from the conclusion of the 42nd AGM to the conclusion of the 47th AGM, subject to shareholder approval.

Key Figures

Effective date of board approvals: July 22, 2026 Statutory auditor term length: five consecutive years AGM range for statutory auditor term: 42nd AGM to 47th AGM

3 metrics

Effective date of board approvals July 22, 2026 Date on which the board approved the management and auditor appointments

Statutory auditor term length five consecutive years Term for Deloitte Haskins & Sells LLP as statutory auditors under the Companies Act, 2013

AGM range for statutory auditor term 42nd AGM to 47th AGM Period from the conclusion of the 42nd AGM to the conclusion of the 47th AGM for Deloitte’s statutory auditor role

Key Terms

Senior Management Personnel, Independent Registered Public Accounting Firm, SEBI Listing Regulations, Nomination, Governance and Compensation Committee, +1 more

5 terms

Senior Management Personnel regulatory

"The updated list of the Company's Senior Management Personnel, reflecting the above appointment"

Independent Registered Public Accounting Firm regulatory

"approved the appointment of M/s Deloitte Haskins & Sells, LLP, as the Independent Registered Public Accounting Firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

SEBI Listing Regulations regulatory

"Pursuant to Regulations 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015"

Nomination, Governance and Compensation Committee regulatory

"Pursuant to the recommendation of the Nomination, Governance and Compensation Committee"

Annual Report on Form 20-F regulatory

"auditing the financial statements of the Company to be included in the Company’s Annual Report on Form 20-F"

An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/22/2026 - 08:31 AM Accepted by SEC EDGAR 07/22/2026 - 08:31 AM Learn about SEC filing dates

FAQ

What corporate changes did Dr. Reddy’s Laboratories (RDY) approve on July 22, 2026?

The board approved two key decisions: appointing Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and appointing Deloitte Haskins & Sells LLP as Independent Registered Public Accounting Firm for Form 20-F and 6-K financial statements.

Who is Dr. Sridevi Khambhampaty and what role will she hold at RDY?

Dr. Sridevi Khambhampaty is an experienced biopharmaceutical leader with over two decades in biologics R&D, quality and business leadership. She has been appointed Global Head of Biologics, designated as Senior Management Personnel, and joins the Management Council effective July 22, 2026.

When does Dr. Sridevi Khambhampaty’s appointment at Dr. Reddy’s (RDY) become effective?

Her appointment as Global Head of Biologics and Senior Management Personnel, and her induction as a Management Council member, is effective July 22, 2026, the date on which the board of directors approved the change at its meeting.

What is Deloitte Haskins & Sells LLP’s role for Dr. Reddy’s (RDY)?

Deloitte Haskins & Sells LLP has been approved as Independent Registered Public Accounting Firm to audit financial statements included in Dr. Reddy’s Annual Report on Form 20-F and to review interim financial statements submitted to the SEC on Form 6-K.

How does Deloitte’s SEC role align with its statutory auditor appointment at RDY?

The SEC role aligns with an earlier decision to appoint Deloitte Haskins & Sells LLP as statutory auditors for a term of five consecutive years, from the conclusion of the 42nd AGM to the 47th AGM, under the Companies Act, 2013.

What governance information about Senior Management Personnel did Dr. Reddy’s (RDY) provide?

Dr. Reddy’s provided an updated list of Senior Management Personnel, including key leaders such as the Chairman, Managing Director, CEO, CFO and business unit heads, and added Dr. Sridevi Khambhampaty as Global Head of Biologics to this list.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                    Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                    No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated July 22, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: July 22, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

July 22, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Lis ting Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulations 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that the Board of Directors of the Company, at its meeting held today, i.e., July 22, 2026, inter alia considered and approved the following:

1. Appointment of Senior Management Personnel

Pursuant to the recommendation of the Nomination, Governance and Compensation Committee, the Board of Directors of the Company, at their meeting held today, approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel of the Company, and her induction as a Member of the Management Council, effective July 22, 2026.

The updated list of the Company's Senior Management Personnel, reflecting the above appointment, is enclosed as Annexure A1.

2. Appointment of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm

This is in continuation of our letter dated May 12, 2026, wherein the Company had informed that it has appointed M/s Deloitte Haskins & Sells, LLP, (Firm Registration No. 117366W/W-100018), as the Statutory Auditors of the Company, in terms of the provisions of Companies Act, 2013, for a term of five consecutive years, commencing from the conclusion of the 42^nd AGM till the conclusion of the 47^th AGM, subject to the approval of the shareholders at the ensuing AGM.

We further wish to inform that to align with the above and basis the recommendation of the Audit Committee, the Board of Directors have approved the appointment of M/s Deloitte Haskins & Sells, LLP, as the Independent Registered Public Accounting Firm of the Company for the purpose of auditing the financial statements of the Company to be included in the Company’s Annual Report on Form 20-F and reviewing the interim financial statements to be filed with the U.S. Securities and Exchange Commission on Form 6-K.

The disclosure required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure A and B.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

  

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above

Annexure A

Details of Dr. Sridevi Khambhampaty

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel of the Company, and her induction as a Member of the Management Council
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	July 22, 2026
3.	Brief profile (in case of appointment)	As mentioned below
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Brief Profile of Dr. Sridevi Khambhampaty

Dr. Sridevi is an accomplished biopharmaceutical leader with over two decades of experience spanning Biologics R&D, Quality, and Business leadership. Most recently, she served as the CEO of Shilpa Biologics, where she led the organization’s growth and strategic direction. Prior to this, she held senior leadership roles at Syngene International and Intas Biopharma.

In her previous stint at Dr Reddy’s, Dr. Sridevi led teams in Product Development and Quality Control at Biologics and contributed to several of our current products in biosimilars. She brings deep expertise in biologics, development strategy, regulatory sciences, and cross-functional leadership, along with extensive experience in building and scaling high-performing teams. She holds a PhD in Biological Sciences from NCBS (TIFR) and completed her postdoctoral research at Stanford University School of Medicine

Annexure A1

List of Senior Management Personnel

Sl.No	Name of the SMP	Designation
1	Mr. Satish Reddy	Chairman and Whole-time Director
2	Mr. G V Prasad	Co-Chairman and Managing Director (KMP)
3	Mr. Erez Israeli	Chief Executive Officer (KMP)
4	Mr. M V Ramana	CEO Global Generics
5	Mr. Sanjay Sharma	Chief Operating Officer
6	Mr. M V Narasimham	Chief Financial Officer (KMP)
7	Mr. Deepak Sapra	Chief Executive Officer, API and Services
8	Mr. Krishna Venkatesh	Global Head of IPDO - Integrated Product Development Organization
9	Mr. Patrick Aghanian	Head - Consumer Health Organization
10	Mr. Phanimitra B	Chief Digital and Information Officer
11	Mr. Milan Kalawadia	Chief Executive Officer, North America
12	Mr. M S Madhu Sundar	Global Head of Quality and PV
13	Mr. Sandeep Khandelwal	Global Generics India Head
14	Dr. Sridevi Khambhampaty	Global Head of Biologics
15	Mr. K Randhir Singh	Company Secretary, Compliance Officer and Head-CSR (KMP)

Annexure B

Details of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Independent Registered

Public Accounting Firm

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	July 22, 2026
3.	Brief profile (in case of appointment)	Deloitte Haskins & Sells, Mumbai was constituted in 1997 and has been converted to a Limited Liability Partnership (LLP), with the name Deloitte Haskins & Sells LLP ("“DHS LLP”" or "“Firm"”), w.e.f. November 20, 2013. DHS LLP is registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018) and is a part of Deloitte Haskins & Sells & Affiliates being the Network of Firms registered with the ICAI. The registered office of the Firm is One International Center, Tower 3, 31st Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400013, Maharashtra, India.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 103.7 KB